{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/malaria-prophylaxis/management/malaria-prevention-in-travellers-from-the-uk/","result":{"pageContext":{"chapter":{"id":"97193dc0-631b-5bea-89f3-7e605df7f3f4","slug":"malaria-prevention-in-travellers-from-the-uk","fullItemName":"Scenario: Malaria prevention in travellers from the UK","depth":2,"htmlHeader":"<!-- begin field cafb6eea-759e-4a06-b02a-25b38188c7cd --><h2>Scenario: Malaria prevention in travellers from the UK</h2><!-- end field cafb6eea-759e-4a06-b02a-25b38188c7cd -->","summary":"Covers the malaria risks, symptoms and what to do if symptoms of malaria develop; personal protective measures; chemoprophylaxis for the country to be visited taking into account contra-indications and co-morbid conditions; when to provide emergency standby treatment; and sources of information for healthcare professionals and the public.","htmlStringContent":"<!-- begin item ab25cdc8-3ad5-4230-ae50-9b330f827fdc --><!-- begin field feb2bd27-bf2f-4593-b123-acbc015a9cb9 --><p>From age 16 years onwards.</p><!-- end field feb2bd27-bf2f-4593-b123-acbc015a9cb9 --><!-- end item ab25cdc8-3ad5-4230-ae50-9b330f827fdc -->","topic":{"id":"1dfdf856-ced9-50bb-8739-9ac597e749da","topicId":"fcbcecf9-c37c-4236-a0f0-e6ea3ff72076","topicName":"Malaria prophylaxis","slug":"malaria-prophylaxis","lastRevised":"Last revised in January 2018","chapters":[{"id":"ce4f76aa-9527-5f8c-9846-98b8c95af6e4","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6fd40a83-7b55-56f4-97de-93dd8ba2ad8f","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"665f9f2c-5318-56d6-ac14-83dd936bdf97","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"62945b37-6310-5a07-b2dc-90e23836e367","slug":"changes","fullItemName":"Changes"},{"id":"57a7f2b1-f3c6-5c7c-be23-60a85ca3e97f","slug":"update","fullItemName":"Update"}]},{"id":"4cbf6005-cbd7-5792-be78-1e08b1755887","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"24cd959e-2b4a-53d8-9a67-2cb6351480d4","slug":"goals","fullItemName":"Goals"},{"id":"8bfd8f1f-5162-55f5-98d0-024aa470eda3","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6e3197bd-4c7e-50e3-8571-464b20b486e6","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"68b0fb84-1d6e-5755-9c2e-89fd57721afa","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"0e6ae722-735b-5e79-85d2-194cb8187380","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"66ce78ae-da4a-51bf-9d51-ae896236d71d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"f8048c7c-b171-5f3b-91f0-2a353065712f","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"0f3bc680-088f-5879-bf5b-9cc85a3ea0ff","slug":"definition","fullItemName":"Definition"},{"id":"b849c9ff-c93f-5656-a227-098952e12f88","slug":"causes","fullItemName":"Causes"},{"id":"caad75c1-ac57-5c45-b040-8526b6235302","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ef83916a-1184-5356-93ba-f9bac26e167a","slug":"prognosis","fullItemName":"Prognosis"},{"id":"a763547a-e2f3-5435-b3e5-36b2b8ad0c9e","slug":"complications","fullItemName":"Complications"}]},{"id":"254e9708-01a9-5862-801a-70f9e1fb5e84","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"3379892e-94c0-5840-a578-cb5766212c69","slug":"assessment","fullItemName":"Assessment"},{"id":"4f391cab-b5f3-563e-be8a-a7235fe6467f","slug":"clinical-features","fullItemName":"Clinical features"}]},{"id":"18712f50-06cc-5638-9851-5c50e65488b5","fullItemName":"Management","slug":"management","subChapters":[{"id":"97193dc0-631b-5bea-89f3-7e605df7f3f4","slug":"malaria-prevention-in-travellers-from-the-uk","fullItemName":"Scenario: Malaria prevention in travellers from the UK"}]},{"id":"7750a127-e87f-5079-8777-0c8f13536296","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d4c5d3cf-2088-5d0a-94a1-af0994185aa5","slug":"drug-availability-on-the-nhs","fullItemName":"Drug availability on the NHS"},{"id":"f0cf5bcc-8534-50cf-a520-0e80e777e72d","slug":"prescribing-in-children","fullItemName":"Prescribing in children"},{"id":"2f74fd56-68c0-56c8-a07c-22482e10e67e","slug":"chloroquine","fullItemName":"Chloroquine"},{"id":"a6e70a24-4baa-514f-9d3a-a7ccb0d9b45c","slug":"proguanil","fullItemName":"Proguanil"},{"id":"2ce163bd-7fa7-51bd-8554-3a6a1cafdfa1","slug":"mefloquine","fullItemName":"Mefloquine"},{"id":"4ca8c124-4f45-50ce-a3b2-9a02219d6ab9","slug":"proguanil-plus-atovaquone","fullItemName":"Proguanil plus atovaquone"},{"id":"57e80cdf-fc37-5774-979d-f58301a7b5fb","slug":"doxycycline","fullItemName":"Doxycycline"}]},{"id":"38b67274-c723-5e50-9cdd-5cc01de962cb","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"91d3306b-2734-52a0-ac13-1adf3711008a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bb5bc365-9c32-5684-9333-e464e129ad67","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"7b7d36b2-37d8-5815-836a-898e104a533e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2d5b97c9-c3d7-51bf-beae-65128d39bd5d","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d69ddbc4-81c8-5404-8a15-7bc2502831cb","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"c2fc1581-dd5f-5317-a19f-cfb72905246e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d7b5a2b6-f6a2-529e-8337-1780d8941d2c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"18712f50-06cc-5638-9851-5c50e65488b5","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"ca41b04e-6dea-5b98-b6f3-ac02343017dc","slug":"overview-of-management","fullItemName":"Overview of management","depth":3,"htmlHeader":"<!-- begin field 69d449b5-bc92-4806-a642-23481d10082a --><h3>How should I manage a person intending to travel to a malaria endemic area?</h3><!-- end field 69d449b5-bc92-4806-a642-23481d10082a -->","summary":null,"htmlStringContent":"<!-- begin item 3bf4852e-4324-42d8-a741-1bb0166b49db --><!-- begin field 63ea0b37-e119-4db3-9781-e417599ef57e --><p><strong>For people intending to travel to a malaria-endemic area:</strong></p><ul><li><strong>Advise avoidance of travel if:</strong><ul><li>The person is at high risk of severe or fatal malaria (for example pregnant women, children, the elderly [aged over 70 years] and those with complex co-morbidities or immunosuppression).<ul><li>If travel is unavoidable, emphasise the importance of rigorous <a class=\"topic-reference internal-reference\" href=\"/topics/malaria-prophylaxis/management/malaria-prevention-in-travellers-from-the-uk/#personal-protective-measures\">personal protective measures</a> and adherence to <a class=\"topic-reference internal-reference\" href=\"/topics/malaria-prophylaxis/management/malaria-prevention-in-travellers-from-the-uk/#chemoprophylaxis\">chemoprophylaxis</a>. Emergency medical attention should be sought immediately if malaria infection is suspected.</li></ul></li></ul></li><li><strong>Give advice and provide written information:</strong><ul><li><strong>Explain the risk factors</strong> for acquiring malaria such as:<ul><li>Exposure to infective bites — risk is increased by being outside between dusk and dawn (when Anopheles mosquitos are likely to bite), longer stays and unscreened accommodation.</li><li>Misconceptions about immunity — immunity acquired by people born in malarious countries is rapidly lost after migration to the UK. Having had malaria in the past does not protect from future attacks — effective <a class=\"topic-reference internal-reference\" href=\"/topics/malaria-prophylaxis/management/malaria-prevention-in-travellers-from-the-uk/#personal-protective-measures\">personal protective measures</a> and <a class=\"topic-reference internal-reference\" href=\"/topics/malaria-prophylaxis/management/malaria-prevention-in-travellers-from-the-uk/#chemoprophylaxis\">chemoprophylaxis</a> are needed for all visits to endemic areas.</li></ul></li><li><strong>Describe the clinical features</strong> of malaria and the importance of prompt diagnosis and early treatment.<ul><li>Malaria can progress from mild to life-threatening disease within hours — if clinical features of malaria develop while travelling or up to one year after return early diagnosis and treatment is essential.</li><li>Children and pregnant women with malaria can deteriorate very rapidly and become critically ill — ensure that all involved in the care of children returning from malarious areas (such as family/carers, school, and healthcare contacts) are aware that urgent medical attention (including a blood test for malaria) is required if the child becomes unwell within a year of leaving the malarious area.</li><li>For information on the <a class=\"topic-reference external-reference\" href=\"/topics/malaria/diagnosis/clinical-features/\">clinical features of malaria</a>, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/malaria/\">Malaria</a>.</li></ul></li><li><strong>Patient information leaflets are available from Public Health England:</strong><ul><li><a href=\"https://www.gov.uk/government/publications/malaria-information-for-people-travellingoverseas\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"8d795661-5e32-4062-a789-a9930064d55c\">Malaria: information for people travelling overseas</a> — available in English, Bengali, Gujarati, Punjabi and Urdu.</li><li><a href=\"https://www.gov.uk/government/publications/travelling-overseas-to-visit-friends-andrelatives-health-advice\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"9bcea429-2e18-43d3-b00a-a9930064d56e\">Travelling overseas to visit friends and relatives?</a></li><li><a href=\"https://www.gov.uk/government/publications/malaria-prevention-transmission-symptoms/malaria-transmission-incubation-period-symptoms#how-to-avoid-getting-malaria\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"f13a77ca-14b1-4260-b5ee-a9930064d583\">Guidance: malaria factsheet.</a></li></ul></li></ul></li><li><strong>Recommend <a class=\"topic-reference internal-reference\" href=\"/topics/malaria-prophylaxis/management/malaria-prevention-in-travellers-from-the-uk/#personal-protective-measures\">personal protective measures</a></strong> to prevent mosquito (and other vector) bites such as:<ul><li>Application of insect repellent containing at least 20% DEET or icardin.</li><li>Protective clothing.</li><li>Insecticide impregnated bed nets.</li></ul></li><li><strong>Consider the need for <a class=\"topic-reference internal-reference\" href=\"/topics/malaria-prophylaxis/management/malaria-prevention-in-travellers-from-the-uk/#chemoprophylaxis\">chemoprophylaxis</a> </strong>risk assessment.<ul><li>If the person has HIV, discuss options for chemoprophylaxis with their HIV physician who will make the decision on choice of agent.</li><li>Ensure that parents/carers understand the importance of ensuring that children take chemoprophylaxis properly and complete the full course — maximum recommended doses must not be exceeded as antimalarials can be particularly toxic to children.</li></ul></li><li><strong>Consider the need for <a class=\"topic-reference internal-reference\" href=\"/topics/malaria-prophylaxis/management/malaria-prevention-in-travellers-from-the-uk/#standby-emergency-medication\">standby emergency medication</a></strong> if the person is visiting a remote area and likely to be more than 24 hours away from medical care.</li><li><strong>If uncertain about management, seek specialist advice:</strong><ul><li><strong>Advice for health care professionals on insect and tick bite avoidance is available from:</strong><ul><li>The <a href=\"https://travelhealthpro.org.uk/factsheet/38/insect-and-tick-bite-avoidance\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"ffe80764-1c2b-49e5-bf1c-a9930064d595\">TravelHealthPro</a> website which contains resources from the National Travel Health Network and Centre (NaTHNaC).</li></ul></li><li><strong>Advice for health care professionals on malaria prophylaxis is available from:</strong><ul><li><a href=\"http://www.malaria-reference.co.uk/\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"7b6c913b-9769-42f9-bad6-a9930064d64f\">Malaria Reference Laboratory</a> (MRL).</li><li><a href=\"http://travelhealthpro.org.uk/\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"63fe1f39-d234-437a-9648-a9930064d68a\">National Travel Health Network and Centre</a> (NaTHNaC).</li><li><a href=\"http://www.travax.nhs.uk/\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"9529bcdd-7a4c-4160-bceb-a9930064d797\">TRAVAX</a> (Health Protection Scotland).</li></ul></li><li><strong>Advice for health care professionals on the diagnosis of malaria is available from:</strong><ul><li>The <a href=\"http://www.malaria-reference.co.uk/\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"ec55000a-ab20-4814-b9cc-a9930064d83b\">Malaria Reference Laboratory</a> (MRL).</li><li>The <a href=\"http://www.thehtd.org/\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"11778d1f-8b36-40a0-8225-a9930064d850\">Hospital for Tropical Diseases</a> (HTD).</li></ul></li><li>Further information on diagnosis and management of malaria and links to sources of expert advice, is available in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/malaria/\">Malaria</a>.</li></ul></li></ul><!-- end field 63ea0b37-e119-4db3-9781-e417599ef57e --><!-- end item 3bf4852e-4324-42d8-a741-1bb0166b49db -->","subChapters":[{"id":"b3970b7f-d474-594e-98ce-621aec66686d","slug":"basis-for-recommendation-d19","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 8f6e4227-e273-482a-8531-1e2a67dc1267 --><h4>Basis for recommendation</h4><!-- end field 8f6e4227-e273-482a-8531-1e2a67dc1267 -->","summary":null,"htmlStringContent":"<!-- begin item d193515a-a109-47be-932f-a76ac114ec77 --><!-- begin field 0b02497b-cf1b-4c65-a5b0-b6f0a0d7d5c2 --><p>The recommendations on management of a person intending to travel to a malaria endemic area are based on the clinical guidelines <em>Summary of recommendations for the prevention of malaria by the Committee to Advise on Tropical Medicine and Travel (CATMAT)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">CATMAT, 2014</a>]<em>, UK malaria treatment guidelines 2016</em>  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">Lalloo et al, 2016</a>],  <em>Guidelines for malaria prevention in travellers from the UK 2017</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">Chiodini, 2017</a>] and the <em>CDC Yellow Book 2018: Health information for international travel</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">CDC, 2018</a>], the Travel Health Pro factsheet <em>Malaria</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">NaTHNaC, 2017</a>] and expert opinion in monographs and review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">Barnett, 2013</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">UKTIS, 2014a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">Alpern, 2016</a>].</p><!-- end field 0b02497b-cf1b-4c65-a5b0-b6f0a0d7d5c2 --><!-- end item d193515a-a109-47be-932f-a76ac114ec77 -->","subChapters":[]}]},{"id":"444a0c3a-1df0-504b-8fae-b25343e95101","slug":"personal-protective-measures","fullItemName":"Personal protective measures","depth":3,"htmlHeader":"<!-- begin field 7966e8f1-4821-447a-8154-a78200781ad4 --><h3>What personal protective measures should I recommend?</h3><!-- end field 7966e8f1-4821-447a-8154-a78200781ad4 -->","summary":null,"htmlStringContent":"<!-- begin item 408a28aa-3f65-4e37-b043-a7820078197a --><!-- begin field 64599c2a-b2b9-474a-9be2-a78200781ad4 --><p><strong>Advise the person that the first line of defence against malaria infection (and other vector-borne diseases) is effective bite prevention. Recommend:</strong></p><ul><li><strong>Application of insect repellents</strong> (such as DEET or Icardin) to exposed areas of skin — repellents must not be ingested, inhaled or come into contact with the eyes or mouth.<ul><li><strong>DEET.</strong><ul><li>DEET (N,N-Diethyl-meta-toluamide) based insect repellents at concentrations over 20% can be used for people over the age of 2 months (unless allergic).</li><li>Duration of protection is 1 to 3 hours for 20% DEET, up to 6 hours for 30% and up to 12 hours for 50%. Duration of protection does not increase for concentrations above 50%.</li><li>DEET can damage some types of plastic (such as watch straps and 'glasses' and plastic jewellery) – the person should not allow these items to come into contact with DEET.</li><li>If both sunscreen and DEET are required, DEET should be applied after the sunscreen. As DEET may induce a reduction in SPF, 30 to 50 SPF sunscreen should be applied to compensate for this.</li></ul></li><li><strong>Alternatives to DEET </strong>— if DEET is not tolerated (or is unavailable), alternative preparations should be used, but few are as effective. Alternatives include:<ul><li>Icardin (picardin) — concentrations of 20 % or higher are needed to protect against bites from Anopheles mosquitoes.</li><li>PMD (p-menthane 3,8 diol [lemon eucalyptus]) — provides about the same level of protection as 15% DEET but period of protection may be shorter.</li><li>3-ethlyaminopropionate — has a shorter duration of protection than DEET.</li></ul></li></ul></li><li><strong>Protective clothing.</strong><ul><li>To minimise skin exposure to biting mosquitoes advise the person to wear full length, loose-fitting clothing with long sleeves, long trousers and socks if out of doors after sunset.</li><li>Clothing can be treated with insecticide (such as permethrin) or cotton clothing sprayed with DEET to reduce biting through clothing (duration of action will be short as DEET is volatile).</li></ul></li><li><strong>Insecticide treated bednets.</strong><ul><li>Insecticide-treated mosquito nets should be used if the person is sleeping outdoors or in unscreened accommodation. Insecticide helps prevent mosquitos biting through the net if the body touches the mesh.<ul><li>Long-lasting pyrethroid insecticide impregnated nets have an expected useful life of at least 3 years.</li><li>Standard nets need to be re-impregnated every 6 to 12 months (depending on how frequently the net is washed) to remain effective.</li></ul></li><li>Bed nets must be free of tears and tucked in under the mattress.</li></ul></li><li><strong>Coils/electric vapourisers.</strong><ul><li>If electricity is available, an electric pyrethroid vapouriser can be used during the night.</li><li>Mosquito coils containing insecticide can be burnt as an alternative to repel and kill mosquitoes but this is not recommended for indoor use.</li></ul></li><li><strong>Insecticide sprays.</strong><ul><li>Pyrethroids (such as permethrin) have a rapid knock-down effect on mosquitoes and can be used to kill resting mosquitoes in a room.</li></ul></li></ul><!-- end field 64599c2a-b2b9-474a-9be2-a78200781ad4 --><!-- end item 408a28aa-3f65-4e37-b043-a7820078197a -->","subChapters":[{"id":"76bda603-a346-5206-90c7-44ab6f200e8f","slug":"basis-for-recommendation-d05","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field c5c6953f-3f01-4ed6-9b20-a78200781ad9 --><h4>Basis for recommendation</h4><!-- end field c5c6953f-3f01-4ed6-9b20-a78200781ad9 -->","summary":null,"htmlStringContent":"<!-- begin item d059b0e0-e324-464c-ba46-a78200781ad9 --><!-- begin field bfc52cbd-d255-447e-be1f-a78200781ad9 --><p>The recommendations on personal protective measures are based on the clinical guidelines <em>Summary of recommendations for the prevention of malaria by the Committee to Advise on Tropical Medicine and Travel (CATMAT)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">CATMAT, 2014</a>], <em>Guidelines for malaria prevention in travellers from the UK 2017</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">Chiodini, 2017</a>] and <em>CDC Yellow Book 2018 Health information for international travel</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">CDC, 2018</a>], the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">BNF 74, 2017</a>] and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">Barnett, 2013</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">Alpern, 2016</a>].</p><h5>Alternatives to DEET</h5><ul><li>Icardin — The Public Health England Advisory Committee on malaria Prevention (ACMP) advises the use of at least a 20% preparation of icardin if used as an alternative to DEET [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">Chiodini, 2017</a>].</li><li>PMD (p-menthane 3,8 diol [lemon eucalyptus]) provides approximately the same level of protection as 15% DEET but duration of protection may be shorter [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">Chiodini, 2017</a>].</li><li>3-ethlyaminopropionate (IR3535) has a shorter duration of protection than DEET.<ul><li>Protection times against Anopheles mosquitos for DEET are 20–25% higher than IR3535 at equal concentrations [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">Chiodini, 2017</a>].</li></ul></li></ul><!-- end field bfc52cbd-d255-447e-be1f-a78200781ad9 --><!-- end item d059b0e0-e324-464c-ba46-a78200781ad9 -->","subChapters":[]}]},{"id":"13ef5fec-c5b2-593e-a066-5dffa85dc811","slug":"chemoprophylaxis","fullItemName":"Chemoprophylaxis","depth":3,"htmlHeader":"<!-- begin field 40df6960-868f-412c-858c-a78200784b15 --><h3>What chemoprophylaxis should I prescribe?</h3><!-- end field 40df6960-868f-412c-858c-a78200784b15 -->","summary":null,"htmlStringContent":"<!-- begin item 1a0ffc6e-0fd8-49a5-b629-a78200784a3c --><!-- begin field 715686ba-e158-4ef8-8468-a78200784b15 --><ul><li><strong>If chemoprophylaxis is required (based on <a class=\"topic-reference internal-reference\" href=\"/topics/malaria-prophylaxis/diagnosis/assessment/\">individual risk assessment</a>):</strong><ul><li>Explain that a combination of mosquito avoidance and chemoprophylaxis will give significant protection against malaria, but no regime is 100% effective.</li><li>Identify chemoprophylactic agents appropriate for the destination and person by:<ul><li>Consulting the <a href=\"https://www.gov.uk/government/publications/malaria-prevention-guidelines-for-travellers-from-the-uk\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"7ccc00d5-4f20-4ab8-b246-a991002f8529\">Public Health England</a> website — the NaTHNaC or TRAVAX websites should be regularly checked for clinical updates as recommendations may change over time even in minimal risk areas.</li></ul></li><li>Discuss the advantages and disadvantages of appropriate chemoprophylaxis regimens with the person.</li><li>Explain the dosing schedule (including the need to take the drug before, during and for some time after visiting a malarious area), adverse effects and any precautions with specific drugs (for example avoidance of sun exposure with doxycycline).</li><li>Recommend that chemoprophylaxis should be obtained from a reputable source in the UK before travel as some antimalarials purchased abroad may be fake or substandard.</li><li>Explain the risks of discontinuation of anti-malarial drugs – fatal malaria has occurred in people who have stopped all chemoprophylaxis or changed to a less effective drug.<ul><li>If significant adverse events are experienced because of the chemoprophylactic agent, advice should be sought from an appropriately experienced health care professional regarding an effective alternative.</li></ul></li></ul></li><li><strong>If the person discontinues chemoprophylaxis on or after return to UK due to side effects:</strong><ul><li>No additional prophylactic drug is needed if atovaquone-proguanil is discontinued before 7 days after return from a malarious area or suppressive prophylaxis (chloroquine, doxycycline, proguanil, mefloquine) is discontinued before completing 4 weeks’ dosage post return.</li><li>The person <em>must</em> be warned that they are at increased risk of malaria compared with those who have completed the full regimen.</li><li>Advice the person to seek urgent medical attention if they become unwell in the first year after return — an urgent blood test for malaria is essential.</li></ul></li></ul><!-- end field 715686ba-e158-4ef8-8468-a78200784b15 --><!-- end item 1a0ffc6e-0fd8-49a5-b629-a78200784a3c -->","subChapters":[{"id":"e6db3c74-4826-5937-9db3-60f693972174","slug":"basis-for-recommendation-278","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field a4afaa67-a816-4724-9aa7-a78200784b19 --><h4>Basis for recommendation</h4><!-- end field a4afaa67-a816-4724-9aa7-a78200784b19 -->","summary":null,"htmlStringContent":"<!-- begin item 27801c9c-60b1-4dd1-928f-a78200784b19 --><!-- begin field 28578929-85d4-4cca-a7e6-a78200784b19 --><p>The recommendations on chemoprophylaxis are based on the clinical guidelines <em>Summary of recommendations for the prevention of malaria by the Committee to Advise on Tropical Medicine and Travel (CATMAT)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">CATMAT, 2014</a>], <em>Guidelines for malaria prevention in travellers from the UK 2017</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">Chiodini, 2017</a>] and <em>CDC Yellow Book 2018 Health information for international travel</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">CDC, 2018</a>] and the Travel Health Pro factsheet <em>Malaria</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">NaTHNaC, 2017</a>].</p><ul><li>A Cochrane review including 20 RCTs (n = 11,470); 35 cohort studies (n = 198,493); and four large retrospective analyses of health records (n = 800,652) concluded that the absolute risk of malaria during short-term travel appears to be low with mefloquine, doxycycline, and atovaquone-proguanil [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">Tickell-Painter, 2017a</a>].</li><li>Prophylactic doses of mefloquine have been associated with rare but serious adverse effects (including psychoses and seizures) but it remains an important prophylactic agent and is well tolerated by most travellers taking it [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">Chiodini, 2017</a>].<ul><li>A systematic review of deaths and parasuicides associated with mefloquine chemoprophylaxis (n = 17 articles) concluded that the number of deaths reliably attributable to prophylactic mefloquine is very low. Two deaths appeared to be idiosyncratic drug reactions (pulmonary fibrosis and exfoliative illness with neutropenia) and the remaining 8 deaths were unlikely to be related to mefloquine, or unclassifiable. A single summary estimate could not be produced as reporting of the data in the available literature was poor [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">Tickell-Painter, 2017b</a>].</li></ul></li></ul><!-- end field 28578929-85d4-4cca-a7e6-a78200784b19 --><!-- end item 27801c9c-60b1-4dd1-928f-a78200784b19 -->","subChapters":[]}]},{"id":"b0d2553a-739f-59a5-b90c-f6682b2ef1c2","slug":"standby-emergency-medication","fullItemName":"Standby emergency medication","depth":3,"htmlHeader":"<!-- begin field 38a34800-5dba-450a-ba2f-a7820078662f --><h3>When should I prescribe standby emergency medication?</h3><!-- end field 38a34800-5dba-450a-ba2f-a7820078662f -->","summary":null,"htmlStringContent":"<!-- begin item 55414822-f215-4868-8e58-a78200786590 --><!-- begin field c52e1e42-6726-423f-b020-a7820078662f --><ul><li><strong>Standby emergency medication is not required for most travellers but should be considered if the person is taking chemoprophylaxis and visiting remote areas which are not within 24 hours of medical facilities.</strong><ul><li>Choose a recommended regimen based on The Advisory Committee on Malaria Prevention (ACMP) which can be found on the <a href=\"https://www.gov.uk/government/publications/malaria-prevention-guidelines-for-travellers-from-the-uk\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"d9fe5275-4510-47a2-a598-a991002f85b9\">Public Health England</a> website.<ul><li>To reduce the risk of drug toxicity and resistance, the drug used for emergency standby medication should be different to the chemoprophylactic drug.</li></ul></li><li>Explain and provide written information on:<ul><li>When to start the medication — standby emergency medication should be started within 24 hours of onset of any clinical features of malaria (such as fever, chills or myalgia). For further information on the <a class=\"topic-reference external-reference\" href=\"/topics/malaria/diagnosis/clinical-features/\">clinical features of malaria</a>, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/malaria/\">Malaria</a>.</li><li>How the medication should be taken (including dosage, interval, and duration of treatment).</li><li>What to do if vomiting occurs on taking the medication — a second full treatment dose of the antimalarial should be taken if vomiting occurs within 30 minutes of taking it (half-dose if vomiting occurs after 30–60 minutes).</li><li>Possible adverse effects.</li><li>How and when to restart chemoprophylaxis — on completion of the standby treatment course, antimalarial chemoprophylaxis should be restarted 1 week after taking the first treatment dose. If quinine is used for standby treatment, mefloquine prophylaxis should be restarted at least twelve hours after the last treatment dose.</li></ul></li><li>Explain that standby emergency medication is <em>not</em> a replacement for chemoprophylaxis and only a temporary measure.<ul><li>A full medical assessment should be sought as soon as possible to exclude other serious causes of symptoms and ensure appropriate treatment.</li></ul></li><li>A patient information leaflet on emergency standby medication is available as part of the Public Health England publication <a href=\"https://www.gov.uk/government/publications/malaria-prevention-guidelines-for-travellers-from-the-uk\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"725ccb99-c664-4ad8-959c-a991002f8639\">Guidelines for malaria prevention in travellers from the UK: 2017</a>.<ul><li>Advise travelling companions to read the leaflet as well in case the person becomes ill and need assistance in following advice.</li></ul></li></ul></li></ul><!-- end field c52e1e42-6726-423f-b020-a7820078662f --><!-- end item 55414822-f215-4868-8e58-a78200786590 -->","subChapters":[{"id":"9bb18773-c1ce-57f1-8c27-b35dba9e1f4c","slug":"basis-for-recommendation-e14","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field f045285a-ec0a-49ea-b6ac-a78200786633 --><h4>Basis for recommendation</h4><!-- end field f045285a-ec0a-49ea-b6ac-a78200786633 -->","summary":null,"htmlStringContent":"<!-- begin item e14b3bb7-4725-47ca-a12d-a78200786633 --><!-- begin field a66be270-f98b-4447-8d15-a78200786633 --><p>The recommendations on standby emergency medication are based on the clinical guidelines <em>Guidelines for malaria prevention in travellers from the UK 2017</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">Chiodini, 2017</a>] and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">Johnson, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/malaria-prophylaxis/references/\">Haditsch, 2016</a>].</p><!-- end field a66be270-f98b-4447-8d15-a78200786633 --><!-- end item e14b3bb7-4725-47ca-a12d-a78200786633 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}